0001104659-16-159827.txt : 20161130
0001104659-16-159827.hdr.sgml : 20161130
20161130195034
ACCESSION NUMBER: 0001104659-16-159827
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161129
FILED AS OF DATE: 20161130
DATE AS OF CHANGE: 20161130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THOMAS PAUL
CENTRAL INDEX KEY: 0001166776
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 162026511
MAIL ADDRESS:
STREET 1: ONE MILLENNIUM WAY
CITY: BRANCHBURG
STATE: NJ
ZIP: 08876
4
1
a4.xml
4
X0306
4
2016-11-29
1
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001166776
THOMAS PAUL
C/O AEGERION PHARMACEUTICALS, INC.
ONE MAIN STREET, SUITE 800
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2016-11-29
4
D
0
36978
D
0
D
Stock Option (Right to Buy)
15.26
2016-11-29
4
D
0
23521
D
2015-08-01
2021-08-01
Common Stock
23521
0
D
Stock Option (Right to Buy)
15.00
2016-11-29
4
D
0
12854
D
2015-06-05
2022-06-05
Common Stock
12854
0
D
Stock Option (Right to Buy)
64.73
2016-11-29
4
D
0
14700
D
2014-06-26
2023-06-26
Common Stock
14700
0
D
Stock Option (Right to Buy)
32.55
2016-11-29
4
D
0
5012
D
2015-06-26
2024-06-26
Common Stock
5012
0
D
Stock Option (Right to Buy)
17.98
2016-11-29
4
D
0
18000
D
2016-06-26
2025-06-26
Common Stock
18000
0
D
Disposed of in exchange for 37,924 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
/s/ Jennifer Fitzpatrick, Attorney-in-fact
2016-11-30